Let’s face it: science can be hard. Our host, Brett Hellman, former soap opera producer and current AbbVie employee, lacks any sort of scientific background and has recurring nightmares of his high school biology class. Now, he is tasked with talking to biopharmaceutical researchers about their work and translating it for the rest of us.
In each episode, Brett will explore some of the toughest and most relevant topics in medical science. This may be, at times, an exercise in frustration for the scientist being interviewed, but listeners will be rewarded with a new understanding not only of science, but about the scientific community at large – with all pretenses stripped down.
Getting Crispy with CRISPR!
It seems the term CRISPR is all over the news these days. But what exactly is CRISPR? Is it a game-changing technology in the field of gene editing? An entrée into a real-life Jurassic World? Or the description of what happens when you leave a bagel in the toaster too long? Brett just doesn’t get it.
In our second episode, Christopher P. Miller, Ph.D., helps Brett understand the revolutionary technology of CRISPR.
Christopher Miller is a director in The Genomics Research Center within target enabling science and technologies, AbbVie. In his current role he oversees teams focused on genomic profiling technologies, functional genomics/genetic screening and target ID/mechanism of action (MOA). The teams collaborate with all AbbVie sites and therapeutic areas to identify and validate new targets and biomarkers and determine mechanisms of action for small molecules with known activities but unknown molecular targets. Miller also serves as point of contact for creation of genetically engineered animal models with external technology providers. Miller received his Ph.D. in Pharmacology from Michigan State University in 1990 then did a post-doc in Molecular Endocrinology at Harvard Medical School/Massachusetts General Hospital in Boston. Miller moved to the biopharmaceutical industry when he joined Genetics Institute in 1996, then Pfizer (Wyeth) as an associate director of Applied Genomics in 2000. Before joining AbbVie in 2014, Miller spent eight years at Bristol Myers-Squibb, first as the director of Functional Genomics and then as the group director of Applied Genomics.